MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Cognitive impairment in Parkinson’s disease

B. Kurbanov (Tashkent, Uzbekistan)

Meeting: 2016 International Congress

Abstract Number: 182

Keywords: Anxiety, Depression, Parkinsonism

Session Information

Date: Monday, June 20, 2016

Session Title: Parkinsonism, MSA, PSP (secondary and parkinsonism-plus)

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To study features of cognitive symptoms in PD, depending on the severity of the disease.

Background: Parkinson’s disease (PD) is shown a wide range of mental disorders, including cognitive, affective, behavioral and psychotic disorders. Psychiatric disorders play a crucial role in the structure of the clinical manifestations of this pathology. So, depression and cognitive disorders are among the major factors that determine the quality of life of patients.

Methods: The research is based on survey data, 58 patients (36 women and 22 men) with Parkinson’s disease without dementia. Verification of the diagnosis carried out in accordance with the ICD-10, heading for a special code BP – G20. We analyzed the clinical stage and the rate of disease progression to determine the presence of postural instability and violations of walk, the distribution of symptoms identified in the limbs, the severity of cognitive impairment (on a scale MMSE), depression (on a scale of Wakefield). The average age of patients was 59,8 ± 1,2 years, variation number ranged from 50 to 65 years. The duration of illness averaged 3,8 ± 0,2 years of age.The control group consisted of 15 healthy persons matched for sex and age with the main group.

Results: According to clinical stage and rate of disease progression by Hyun and Yar (1967) Stage 1 PSU was set at 41.4% (24) patients with stage 2 BP – 36.2% (21 patients) and Stage 3 BP – from 22.4 % of patients (13). We obtained the following data characterizing the emotional disorders in patients with PD. The average level of depression in PD was 27,9 ± 0,5 points. The normal value of this indicator in the control group was 12 ± 0,2 points. Average depression in patients with 1 tbsp BP was -27,4 ± 0,5 points, with 2 tbsp. BP – 32,4 0,6 points, whereas in Article 3. BP, the figure rose to 35 ± 0,4 points. In patients with PD, there is an increase in the level of depression, depending on the progression of the disease. The assessment of cognitive status was carried out by a short scale MMSE. In the control group of mental status indicators on the MMSE showed the amount of points equal to 29,5 ± 0,1, which was close to that of normal (30 points). In all patients, patients with PD score was equal to 23,6 ± 0,1 (P <0,001).

Conclusions: Thus, anxiety and depression, cognitive impairment are recorded regularly in patients suffering from Parkinson’s disease. Intensity of these syndromes depends on the stage of PD and its progression.

To cite this abstract in AMA style:

B. Kurbanov. Cognitive impairment in Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/cognitive-impairment-in-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/cognitive-impairment-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley